A Pharmacoeconomic Approach in Comparison of Cilnidipine and Metoprolol Succinate, Telmisartan and Hydrochlorothiazide in the Treatment of Hypertensive Patients by application of Cost-Effective Analysis

Abstract

Objective: A study was conducted to evaluate and compare the cost-effectiveness of telmisartan and hydrochlorothiazide
compared with cilnidipine and metoprolol in reducing blood pressure by one mm of Hg per day in hypertensive patients.
Materials and Methods: It was a prospective experimental analysis of cost-effectiveness, to compare the cost of
telmisartan (40 mg), hydrochlorothiazide (12.5mg) and cilnidipine (10 mg) and metoprolol (50 mg) in hypertensive cases
using either of the medicines. An aggregate of 98 cases recently detected hypertensive cases were considered for the
comparison, of which 49 cases were specified telmisartan, hydrochlorothiazide and the other 49 were specified cilidipine,
metoprolol as per the recommended dosage. Data were analyzed using paired and unmatched T-tests in MS- Excel soft
earthenware. Results: The cost of reducing 1mm of Hg blood pressure per day with telmisartan, hydrochlorothiazide was
0.21(SBP), 0.31 (DBP) INR, whereas that of cilidipine, metoprolol was 0.23 (SBP), 0.28 (DBP) INR. Conclusion: This
pharmaco-economic analysis shows that Telmisartan, Hydrochlorothiazide is further cost-effective as compared to
Cilnidipine, Metoprolol succinate when the cost per reduction in blood pressure per day is considered. This may affect the
cases economically during their long-term use of these motes for the hypertension